Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids

• Status: Active, not recruiting
• Trial end date: 2021-10-29
• Target enrollment: 0
• Participant gender: Female

Summary

The study was performed to assess the efficacy and safety of Vilaprisan in subjects with uterine fibroids compared to standard of care

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer

Criteria

Inclusion Criteria:

• 18 years or older

• Diagnosis of uterine fibroid(s) documented by ultrasound at screening AND/OR during a uterine preserving procedure within 3 months prior to screening in subjects with high risk for recurrence

• At least one symptom of uterine fibroid(s) - bleeding, pelvic pressure/pain

• Good general health

• Normal or clinically insignificant cervical smear

• An endometrial biopsy performed during the screening period, without significant histological disorder

• Use of an acceptable nonhormonal method of contraception starting at Visit 1 until the end of the study

Exclusion Criteria:

• Pregnancy or lactation (less than 3 months since delivery, abortion, or lactation before start of treatment)

• Hypersensitivity to any ingredient of the study drug

• Any condition requiring immediate blood transfusion

• Any diseases, conditions, or medications that can compromise the function of the body systems and could result in altered absorption, excessive accumulation, impaired metabolism, or altered excretion of the study drug

• Any diseases or conditions that might interfere with the conduct of the study or the interpretation of the results

• Abuse of alcohol, drugs, or medicines (eg, laxatives)

• Use of other treatments that might interfere with the conduct of the study or the interpretation of the results

• Undiagnosed abnormal genital bleeding